Comparison of Gene Expression Patterns Between Mouse Models of Nonalcoholic Fatty Liver Disease and Liver Tissues From Patients

Gastroenterology

Volumn 151, Issue 3, 2016, Pages 513-525.e0

  Teufel, Andreas ^a   Itzel, Timo ^a   Erhart, Wiebke ^b   Brosch, Mario ^c   Wang, Xiao Yu ^e   Kim, Yong Ook ^e   von Schönfels, Witigo ^b   Herrmann, Alexander ^b   Brückner, Stefan ^c   Stickel, Felix ^f   Dufour, Jean François ^f   Chavakis, Triantafyllos ^d   Hellerbrand, Claus ^a   Spang, Rainer ^g   Maass, Thorsten ^a   Becker, Thomas ^b   Schreiber, Stefan ^b   Schafmayer, Clemens ^b   Schuppan, Detlef ^e,h   Hampe, Jochen ^c  

^a UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^c UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^d DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^e UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^f UNIVERSITY OF BERN   (Switzerland)

^g UNIVERSITY OF REGENSBURG   (Germany)

^h HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Comparative; Cross Species Analysis; Steatosis; Transcriptome

Indexed keywords

ALKALINE PHOSPHATASE; BHLHA15 PROTEIN; CAPN12 PROTEIN; CHOLINE; CYP2F1 PROTEIN; F7 PROTEIN; FRUCTOSE; HAL PROTEIN; IFITM3 PROTEIN; LIPID; LRFN3 PROTEIN; MESSENGER RNA; METHIONINE; MGST3 PROTEIN; NIT2 PROTEIN; NUCB1 PROTEIN; PEPTIDES AND PROTEINS; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PPP1R3B PROTEIN; PROS1 PROTEIN; PUF60 PROTEIN; RNF145 PROTEIN; SRD5A3 PROTEIN; STMN2 PROTEIN; STREPTOZOCIN; TIMM17A PROTEIN; TNFAIP1 PROTEIN; TRANSCRIPTOME; TRYPTOPHAN 2,3 DIOXYGENASE; UNCLASSIFIED DRUG; VIMP PROTEIN;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BARIATRIC SURGERY; CLINICAL EVALUATION; CONTROLLED STUDY; DISEASE COURSE; FEMALE; GENE CONTROL; GENE DISRUPTION; GENE EXPRESSION PROFILING; GENOME-WIDE ASSOCIATION STUDY; HUMAN; HUMAN TISSUE; HUMAN VERSUS ANIMAL COMPARISON; LIPID DIET; LIPID METABOLISM; LIVER; LIVER BIOPSY; LIVER SURGERY; MAJOR CLINICAL STUDY; MALE; MOUSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TRANSCRIPTOMICS; WESTERN DIET; ANIMAL; BIOPSY; C57BL MOUSE; CASE CONTROL STUDY; DIET; DISEASE MODEL; GENETICS; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; PATHOLOGY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; BIOPSY; CASE-CONTROL STUDIES; DIET; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION PROFILING; HUMANS; LIVER; MALE; MICE; MICE, INBRED C57BL; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; RNA, MESSENGER; STREPTOZOCIN; TRANSCRIPTOME;

EID: 84995463461     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2016.05.051     Document Type: Article

References (36)

1. 1 Ong, J.P., Younossi, Z.M., Epidemiology and natural history of NAFLD and NASH. Clin Liver Dis 11 (2007), 1–16 vii.
2. 2 Wong, V.W., Chan, H.L., Hui, A.Y., et al. Clinical and histological features of non-alcoholic fatty liver disease in Hong Kong Chinese. Aliment Pharmacol Ther 20 (2004), 45–49.
3. 3 Wong, V.W., Wong, G.L., Choi, P.C., et al. Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years. Gut 59 (2010), 969–974.
4. 4 Hebbard, L., George, J., Animal models of nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol 8 (2011), 35–44.
5. 5 Imajo, K., Yoneda, M., Kessoku, T., et al. Rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Int J Mol Sci 14 (2013), 21833–21857.
6. 6 Takahashi, Y., Soejima, Y., Fukusato, T., Animal models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. World J Gastroenterol 18 (2012), 2300–2308.
7. 7 Kohli, R., Kirby, M., Xanthakos, S.A., et al. High-fructose, medium chain trans fat diet induces liver fibrosis and elevates plasma coenzyme Q9 in a novel murine model of obesity and nonalcoholic steatohepatitis. Hepatology 52 (2010), 934–944.
8. 8 Lo, L., McLennan, S.V., Williams, P.F., et al. Diabetes is a progression factor for hepatic fibrosis in a high fat fed mouse obesity model of non-alcoholic steatohepatitis. J Hepatol 55 (2011), 435–444.
9. 9 Liu, W., Baker, S.S., Baker, R.D., et al. Upregulation of hemoglobin expression by oxidative stress in hepatocytes and its implication in nonalcoholic steatohepatitis. PLoS One, 6, 2011, e24363.
10. 10 Lake, A.D., Novak, P., Fisher, C.D., et al. Analysis of global and absorption, distribution, metabolism, and elimination gene expression in the progressive stages of human nonalcoholic fatty liver disease. Drug Metab Dispos 39 (2011), 1954–1960.
11. 11 Stefano, J.T., de Oliveira, C.P., Correa-Giannella, M.L., et al. Decreased immunoexpression of survivin could be a potential marker in human non-alcoholic fatty liver disease progression?. Liver Int 31 (2011), 377–385.
12. 12 Yoneda, M., Endo, H., Mawatari, H., et al. Gene expression profiling of non-alcoholic steatohepatitis using gene set enrichment analysis. Hepatol Res 38 (2008), 1204–1212.
13. 13 Rubio, A., Guruceaga, E., Vazquez-Chantada, M., et al. Identification of a gene-pathway associated with non-alcoholic steatohepatitis. J Hepatol 46 (2007), 708–718.
14. 14 Kleiner, D.E., Brunt, E.M., Van Natta, M., et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41 (2005), 1313–1321.
15. 15 Popov, Y., Sverdlov, D.Y., Sharma, A.K., et al. Tissue transglutaminase does not affect fibrotic matrix stability or regression of liver fibrosis in mice. Gastroenterology 140 (2011), 1642–1652.
16. 16 Larter, C.Z., Yeh, M.M., Williams, J., et al. MCD-induced steatohepatitis is associated with hepatic adiponectin resistance and adipogenic transformation of hepatocytes. J Hepatol 49 (2008), 407–416.
17. 17 Rinella, M.E., Green, R.M., The methionine-choline deficient dietary model of steatohepatitis does not exhibit insulin resistance. J Hepatol 40 (2004), 47–51.
18. 18 Dorn, C., Engelmann, J.C., Saugspier, M., et al. Increased expression of c-Jun in nonalcoholic fatty liver disease. Lab Invest 94 (2014), 394–408.
19. 19 Stiles, B., Wang, Y., Stahl, A., et al. Liver-specific deletion of negative regulator Pten results in fatty liver and insulin hypersensitivity [corrected]. Proc Natl Acad Sci U S A 101 (2004), 2082–2087.
20. 20 Horie, Y., Suzuki, A., Kataoka, E., et al. Hepatocyte-specific Pten deficiency results in steatohepatitis and hepatocellular carcinomas. J Clin Invest 113 (2004), 1774–1783.
21. 21 Guberman, J.M., Ai, J., Arnaiz, O., et al. BioMart Central Portal: an open database network for the biological community. Database (Oxford), 2011, 2011, bar041.
22. 22 NCBI Resource Coordinators. Database resources of the National Center for Biotechnology Information. Nucleic Acids Res 42 (2014), D7–D17.
23. 23 Blake, J.A., Bult, C.J., Eppig, J.T., et al. The Mouse Genome Database: integration of and access to knowledge about the laboratory mouse. Nucleic Acids Res 42 (2014), D810–D817.
24. 24 Gray, K.A., Daugherty, L.C., Gordon, S.M., et al. Genenames.org: the HGNC resources in 2013. Nucleic Acids Res 41 (2013), D545–D552.
25. 25 Subramanian, A., Tamayo, P., Mootha, V.K., et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 102 (2005), 15545–15550.
26. 26 Seok, J., Warren, H.S., Cuenca, A.G., et al. Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc Natl Acad Sci U S A 110 (2013), 3507–3512.
27. 27 Gao, D., Wei, C., Chen, L., et al. Oxidative DNA damage and DNA repair enzyme expression are inversely related in murine models of fatty liver disease. Am J Physiol Gastrointest Liver Physiol 287 (2004), G1070–G1077.
28. 28 Dietrich, P., Hellerbrand, C., Non-alcoholic fatty liver disease, obesity and the metabolic syndrome. Best Pract Res Clin Gastroenterol 28 (2014), 637–653.
29. 29 Ahrens, M., Ammerpohl, O., von Schonfels, W., et al. DNA methylation analysis in nonalcoholic fatty liver disease suggests distinct disease-specific and remodeling signatures after bariatric surgery. Cell Metab 18 (2013), 296–302.
30. 30 Hedbacker, K., Birsoy, K., Wysocki, R.W., et al. Antidiabetic effects of IGFBP2, a leptin-regulated gene. Cell Metab 11 (2010), 11–22.
31. 31 Moylan, C.A., Pang, H., Dellinger, A., et al. Hepatic gene expression profiles differentiate presymptomatic patients with mild versus severe nonalcoholic fatty liver disease. Hepatology 59 (2014), 471–482.
32. 32 Wang, G., Li, B., Hao, Y., et al. Correlation analysis between gene expression profile of high-fat emulsion-induced non-alcoholic fatty liver and liver regeneration in rat. Cell Biol Int 37 (2013), 917–928.
33. 33 Kirpich, I.A., Gobejishvili, L.N., Bon Homme, M., et al. Integrated hepatic transcriptome and proteome analysis of mice with high-fat diet-induced nonalcoholic fatty liver disease. J Nutr Biochem 22 (2011), 38–45.
34. 34 Ertle, J., Dechene, A., Sowa, J.P., et al. Non-alcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis. Int J Cancer 128 (2011), 2436–2443.
35. 35 Page, J.M., Harrison, S.A., NASH and HCC. Clin Liver Dis 13 (2009), 631–647.
36. 36 Starley, B.Q., Calcagno, C.J., Harrison, S.A., Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology 51 (2010), 1820–1832.